stockrowTrulieve Cannabis Corp.
TRLV Healthcare Drug Manufacturers Specialty & Generic
Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- −20.1%
- EPS
- −2,391.1%
- Free cash flow
- +24.5%
- Total debt
- −37.0%
Quarter to September 2026, against a year earlier
Follow TRLV
Alert me
Trulieve Cannabis Corp. (TRLV) Return on assets
Trulieve Cannabis Corp.'s return on assets over the twelve months to 30 September 2026 was −17.6%, down 13.4 percentage points from fiscal 2025 (−4.18%). Over the past ten years it has ranged from −17.2% (fiscal 2023) to 0.00% (fiscal 2021); the current reading is higher than 67% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of −1.67% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −4.18% | 1.36 |
| FY2024 | −5.54% | 11.65 |
| FY2023 | −17.2% | (9.97) |
| FY2022 | −7.22% | (7.22) |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ANIP ANI Pharmaceuticals, Inc. compare | 7.85% |
| PBH Prestige Consumer Healthcare Inc. compare | 3.80% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| ALVO Alvotech compare | 0.00% |
| XERS Xeris Biopharma Holdings, Inc. compare | −1.64% |
| TRLV Trulieve Cannabis Corp. | −17.6% |
| PRGO Perrigo Company plc compare | −20.2% |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −69.3% |
| Drug Manufacturers Specialty & Generic industry median | −1.67% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on TRLV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement